- $7.68m
- -$11.32m
- $0.08m
Brief: Aclarion, ATEC Execute Strategic Partnership Agreement
Brief: Aclarion Announces Reverse Stock Split
U.S. STOCKS ON THE MOVE-Bluebird bio, Cinemark Holdings, Steelcase Inc
Brief: Aclarion Files For Offering Of 25.9 Mln Units
Brief: Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders to Support Nociscan Adoption
Alphatec tumbles on pricing $150 mln stock offering
Brief: Aclarion Signs Strategic Partnership Letter of Intent With ATEC
Brief: Aclarion Provides Updated Investor Presentation And Corporate Update
Brief: Aclarion Says On August 23 Received A Notice From Nasdaq That Company No Longer Complied With Nasdaq Listing Rule 5250(C)(1)
Brief: Aclarion, Inc. Announces Filing Of Delayed 10-Q Quarterly Report
Brief: Aclarion Received A Letter From Nasdaq Indicating That Co Was Now In Compliance With Nasdaq Listing Rule 5250(C)(1)
Brief: Aclarion Notified By Nasdaq On June 15 That Company Had Regained Compliance With Minimum Bid Price Requirement
U.S. STOCKS ON THE MOVE-Constellation Energy, Cactus, Cardinal Health
U.S. STOCKS ON THE MOVE-CureVac, Aclarion, Baosheng Media
U.S. STOCKS ON THE MOVE-Carvana, Annovis Bio, Aclarion
Aclarion up as data shows cost-effectiveness of its back pain detection system
Brief: Aclarion Inc Announces Delayed 10-Q Filing
Brief: Aclarion Announces Non-Convertible Debt Financing To Achieve Three Critical Catalysts
Brief: Aclarion Inc - On May 15, Concluded Previously Issued Audited Financial Statements For Year Ended December 31, 2022 Should No Longer Be Relied Upon